1
|
Chen X. Enabling Chemoenzymatic Strategies and Enzymes for Synthesizing Sialyl Glycans and Sialyl Glycoconjugates. Acc Chem Res 2024; 57:234-246. [PMID: 38127793 PMCID: PMC10795189 DOI: 10.1021/acs.accounts.3c00614] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 12/04/2023] [Accepted: 12/04/2023] [Indexed: 12/23/2023]
Abstract
Sialic acids are fascinating negatively charged nine-carbon monosaccharides. Sialic acid-containing glycans and glycoconjugates are structurally diverse, functionally important, and synthetically challenging molecules. We have developed highly efficient chemoenzymatic strategies that combine the power of chemical synthesis and enzyme catalysis to make sialic acids, sialyl glycans, sialyl glycoconjugates, and their derivatives more accessible, enabling the efforts to explore their functions and applications. The Account starts with a brief description of the structural diversity and the functional importance of naturally occurring sialic acids and sialosides. The development of one-pot multienzyme (OPME) chemoenzymatic sialylation strategies is then introduced, highlighting its advantages in synthesizing structurally diverse sialosides with a sialyltransferase donor substrate engineering tactic. With the strategy, systematic access to sialosides containing different sialic acid forms with modifications at C3/4/5/7/8/9, various internal glycans, and diverse sialyl linkages is now possible. Also briefly described is the combination of the OPME sialylation strategy with bacterial sialidases for synthesizing sialidase inhibitors. With the goal of simplifying the product purification process for enzymatic glycosylation reactions, glycosphingolipids that contain a naturally existing hydrophobic tag are attractive targets for chemoenzymatic total synthesis. A user-friendly highly efficient chemoenzymatic strategy is developed which involves three main processes, including chemical synthesis of lactosyl sphingosine as a water-soluble hydrophobic tag-containing intermediate, OPME enzymatic extension of its glycan component with a single C18-cartridge purification of the product, followed by a facile chemical acylation reaction. The strategy allows the introduction of different sialic acid forms and diverse fatty acyl chains into the products. Gram-scale synthesis has been demonstrated. OPME sialylation has also been demonstrated for the chemoenzymatic synthesis of sialyl glycopeptides and in vitro enzymatic N-glycan processing for the formation of glycoproteins with disialylated biantennary complex-type N-glycans. For synthesizing human milk oligosaccharides (HMOs) which are glycans with a free reducing end, acceptor substrate engineering and process engineering strategies are developed, which involve the design of a hydrophobic tag that can be easily installed into the acceptor substrate to allow facile purification of the product from enzymatic reactions and can be conveniently removed in the final step to produce target molecules. The process engineering involves heat-inactivation of enzymes in the intermediate steps in multistep OPME reactions for the production of long-chain sialoside targets in a single reaction pot and with a single C18-cartridge purification process. In addition, a chemoenzymatic synthon strategy has been developed. It involves the design of a derivative of the sialyltransferase donor substrate precursor, which is tolerated by enzymes in OPME reactions, introduced to enzymatic products, and then chemically converted to the desired target structures in the final step. The chemoenzymatic synthon approach has been used together with the acceptor substrate engineering method in the synthesis of complex bacterial glycans containing sialic acids, legionaminic acids, and derivatives. The biocatalysts characterized and their engineered mutants developed by the Chen group are described, with highlights on synthetically useful enzymes. We anticipate further development of chemoenzymatic strategies and biocatalysts to enable exploration of the sialic acid space.
Collapse
Affiliation(s)
- Xi Chen
- Department of Chemistry, University of California, Davis, California 95616, United States
| |
Collapse
|
2
|
Bose P, Jaiswal MK, Singh SK, Singh RK, Tiwari VK. Growing impact of sialic acid-containing glycans in future drug discovery. Carbohydr Res 2023; 527:108804. [PMID: 37031650 DOI: 10.1016/j.carres.2023.108804] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 03/21/2023] [Accepted: 03/29/2023] [Indexed: 04/05/2023]
Abstract
In nature, almost all cells are covered with a complex array of glycan chain namely sialic acids or nuraminic acids, a negatively charged nine carbon sugars which is considered for their great therapeutic importance since long back. Owing to its presence at the terminal end of lipid bilayer (commonly known as terminal sugars), the well-defined sialosides or sialoconjugates have served pivotal role on the cell surfaces and thus, the sialic acid-containing glycans can modulate and mediate a number of imperative cellular interactions. Understanding of the sialo-protein interaction and their roles in vertebrates in regard of normal physiology, pathological variance, and evolution has indeed a noteworthy journey in medicine. In this tutorial review, we present a concise overview about the structure, linkages in chemical diversity, biological significance followed by chemical and enzymatic modification/synthesis of sialic acid containing glycans. A more focus is attempted about the recent advances, opportunity, and more over growing impact of sialosides and sialoconjugates in future drug discovery and development.
Collapse
|
3
|
Keil J, Rafn GR, Turan IM, Aljohani MA, Sahebjam-Atabaki R, Sun XL. Sialidase Inhibitors with Different Mechanisms. J Med Chem 2022; 65:13574-13593. [PMID: 36252951 PMCID: PMC9620260 DOI: 10.1021/acs.jmedchem.2c01258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Indexed: 11/28/2022]
Abstract
Sialidases, or neuraminidases, are enzymes that catalyze the hydrolysis of sialic acid (Sia)-containing molecules, mostly removal of the terminal Sia (desialylation). By desialylation, sialidase can modulate the functionality of the target compound and is thus often involved in biological pathways. Inhibition of sialidases with inhibitors is an important approach for understanding sialidase function and the underlying mechanisms and could serve as a therapeutic approach as well. Transition-state analogues, such as anti-influenza drugs oseltamivir and zanamivir, are major sialidase inhibitors. In addition, difluoro-sialic acids were developed as mechanism-based sialidase inhibitors. Further, fluorinated quinone methide-based suicide substrates were reported. Sialidase product analogue inhibitors were also explored. Finally, natural products have shown competitive inhibiton against viral, bacterial, and human sialidases. This Perspective describes sialidase inhibitors with different mechanisms and their activities and future potential, which include transition-state analogue inhibitors, mechanism-based inhibitors, suicide substrate inhibitors, product analogue inhibitors, and natural product inhibitors.
Collapse
Affiliation(s)
- Joseph
M. Keil
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| | - Garrett R. Rafn
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| | - Isaac M. Turan
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| | - Majdi A. Aljohani
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| | - Reza Sahebjam-Atabaki
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| | - Xue-Long Sun
- Department of Chemistry, Chemical and
Biomedical Engineering and Center for Gene Regulation in Health and
Disease (GRHD), Cleveland State University, Cleveland, Ohio 44115, United States
| |
Collapse
|
4
|
Abstract
![]()
Fluorinated
carbohydrates have found many applications in the glycosciences.
Typically, these contain fluorination at a single position. There
are not many applications involving polyfluorinated carbohydrates,
here defined as monosaccharides in which more than one carbon has
at least one fluorine substituent directly attached to it, with the
notable exception of their use as mechanism-based inhibitors. The
increasing attention to carbohydrate physical properties, especially
around lipophilicity, has resulted in a surge of interest for this
class of compounds. This review covers the considerable body of work
toward the synthesis of polyfluorinated hexoses, pentoses, ketosugars,
and aminosugars including sialic acids and nucleosides. An overview
of the current state of the art of their glycosidation is also provided.
Collapse
Affiliation(s)
- Kler Huonnic
- School of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, U.K
| | - Bruno Linclau
- School of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, U.K.,Department of Organic and Macromolecular Chemistry, Ghent University, Campus Sterre, Krijgslaan 281-S4, Ghent, 9000, Belgium
| |
Collapse
|
5
|
Bowles WHD, Gloster TM. Sialidase and Sialyltransferase Inhibitors: Targeting Pathogenicity and Disease. Front Mol Biosci 2021; 8:705133. [PMID: 34395532 PMCID: PMC8358268 DOI: 10.3389/fmolb.2021.705133] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 07/12/2021] [Indexed: 12/15/2022] Open
Abstract
Sialidases (SAs) and sialyltransferases (STs), the enzymes responsible for removing and adding sialic acid to other glycans, play essential roles in viruses, bacteria, parasites, and humans. Sialic acid is often the terminal sugar on glycans protruding from the cell surface in humans and is an important component for recognition and cell function. Pathogens have evolved to exploit this and use sialic acid to either “cloak” themselves, ensuring they remain undetected, or as a mechanism to enable release of virus progeny. The development of inhibitors against SAs and STs therefore provides the opportunity to target a range of diseases. Inhibitors targeting viral, bacterial, or parasitic enzymes can directly target their pathogenicity in humans. Excellent examples of this can be found with the anti-influenza drugs Zanamivir (Relenza™, GlaxoSmithKline) and Oseltamivir (Tamiflu™, Roche and Gilead), which have been used in the clinic for over two decades. However, the development of resistance against these drugs means there is an ongoing need for novel potent and specific inhibitors. Humans possess 20 STs and four SAs that play essential roles in cellular function, but have also been implicated in cancer progression, as glycans on many cancer cells are found to be hyper-sialylated. Whilst much remains unknown about how STs function in relation to disease, it is clear that specific inhibitors of them can serve both as tools to gain a better understanding of their activity and form the basis for development of anti-cancer drugs. Here we review the recent developments in the design of SA and ST inhibitors against pathogens and humans.
Collapse
Affiliation(s)
- William H D Bowles
- Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
| | - Tracey M Gloster
- Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews, United Kingdom
| |
Collapse
|
6
|
Assailly C, Bridot C, Saumonneau A, Lottin P, Roubinet B, Krammer EM, François F, Vena F, Landemarre L, Alvarez Dorta D, Deniaud D, Grandjean C, Tellier C, Pascual S, Montembault V, Fontaine L, Daligault F, Bouckaert J, Gouin SG. Polyvalent Transition-State Analogues of Sialyl Substrates Strongly Inhibit Bacterial Sialidases*. Chemistry 2021; 27:3142-3150. [PMID: 33150981 DOI: 10.1002/chem.202004672] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Indexed: 11/06/2022]
Abstract
Bacterial sialidases (SA) are validated drug targets expressed by common human pathogens such as Streptococcus pneumoniae, Vibrio cholerae, or Clostridium perfringens. Noncovalent inhibitors of bacterial SA capable of reaching the submicromolar level are rarely reported. In this work, multi- and polyvalent compounds are developed, based on the transition-state analogue 2-deoxy-2,3-didehydro-N-acetylneuraminic (DANA). Poly-DANA inhibits the catalytic activity of SA from S. pneumoniae (NanA) and the symbiotic microorganism B. thetaiotaomicron (BtSA) at the picomolar and low nanomolar levels (expressed in moles of molecules and of DANA, respectively). Each DANA grafted to the polymer surpasses the inhibitory potential of the monovalent analogue by more than four orders of magnitude, which represents the highest multivalent effect reported so far for an enzyme inhibition. The synergistic interaction is shown to operate exclusively in the catalytic domain, and not in the flanked carbohydrate-binding module (CBM). These results offer interesting perspectives for the multivalent inhibition of other SA families lacking a CBM, such as viral, parasitic, or human SA.
Collapse
Affiliation(s)
- Coralie Assailly
- CNRS, CEISAM UMR, 6230, Université de Nantes, 44000, Nantes, France
| | - Clarisse Bridot
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS, Université de Lille, Lille, 59000, France
| | - Amélie Saumonneau
- UFIP, UMR CNRS 6286, UFR des Sciences et des Techniques, Université de Nantes, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Paul Lottin
- Institut des Molécules et Matériaux du Mans (IMMM), UMR 6283 CNRS, Le Mans Université, Av. O. Messiaen, 72085, Le Mans cedex 9, France
| | - Benoit Roubinet
- Glycodiag, Bâtiment Physique-Chimie, Rue de Chartres, BP6759, 45067, Orléans cedex 2, France
| | - Eva-Maria Krammer
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS, Université de Lille, Lille, 59000, France
| | - Francesca François
- Institut des Molécules et Matériaux du Mans (IMMM), UMR 6283 CNRS, Le Mans Université, Av. O. Messiaen, 72085, Le Mans cedex 9, France
| | - Federica Vena
- Glycodiag, Bâtiment Physique-Chimie, Rue de Chartres, BP6759, 45067, Orléans cedex 2, France
| | - Ludovic Landemarre
- Glycodiag, Bâtiment Physique-Chimie, Rue de Chartres, BP6759, 45067, Orléans cedex 2, France
| | | | - David Deniaud
- CNRS, CEISAM UMR, 6230, Université de Nantes, 44000, Nantes, France
| | - Cyrille Grandjean
- UFIP, UMR CNRS 6286, UFR des Sciences et des Techniques, Université de Nantes, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Charles Tellier
- UFIP, UMR CNRS 6286, UFR des Sciences et des Techniques, Université de Nantes, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Sagrario Pascual
- Institut des Molécules et Matériaux du Mans (IMMM), UMR 6283 CNRS, Le Mans Université, Av. O. Messiaen, 72085, Le Mans cedex 9, France
| | - Véronique Montembault
- Institut des Molécules et Matériaux du Mans (IMMM), UMR 6283 CNRS, Le Mans Université, Av. O. Messiaen, 72085, Le Mans cedex 9, France
| | - Laurent Fontaine
- Institut des Molécules et Matériaux du Mans (IMMM), UMR 6283 CNRS, Le Mans Université, Av. O. Messiaen, 72085, Le Mans cedex 9, France
| | - Franck Daligault
- UFIP, UMR CNRS 6286, UFR des Sciences et des Techniques, Université de Nantes, 2 rue de la Houssinière, BP 92208, 44322, Nantes Cedex 3, France
| | - Julie Bouckaert
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR8576 CNRS, Université de Lille, Lille, 59000, France
| | | |
Collapse
|
7
|
Mahal A, Duan M, Zinad DS, Mohapatra RK, Obaidullah AJ, Wei X, Pradhan MK, Das D, Kandi V, Zinad HS, Zhu Q. Recent progress in chemical approaches for the development of novel neuraminidase inhibitors. RSC Adv 2021; 11:1804-1840. [PMID: 35424082 PMCID: PMC8693540 DOI: 10.1039/d0ra07283d] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 11/22/2020] [Indexed: 12/28/2022] Open
Abstract
Influenza virus is the main cause of an infectious disease called influenza affecting the respiratory system including the throat, nose and lungs. Neuraminidase inhibitors are reagents used to block the enzyme called neuraminidase to prevent the influenza infection from spreading. Neuraminidase inhibitors are widely used in the treatment of influenza infection, but still there is a need to develop more potent agents for the more effective treatment of influenza. Complications of the influenza disease lead to death, and one of these complications is drug resistance; hence, there is an urgent need to develop more effective agents. This review focuses on the recent advances in chemical synthesis pathways used for the development of new neuraminidase agents along with the medicinal aspects of chemically modified molecules, including the structure-activity relationship, which provides further rational designs of more active small molecules.
Collapse
Affiliation(s)
- Ahmed Mahal
- Department of Medical Biochemical Analysis, College of Health Technology, Cihan University-Erbil Erbil Kurdistan Region Iraq
- Key Laboratory of Plant Resources Conservation and Sustainable Utilization, Guangdong Provincial Key Laboratory of Applied Botany, Chinese Academy of Sciences South China Botanical Garden Guangzhou 510650 People's Republic of China
- Guangzhou HC Pharmaceutical Co., Ltd Guangzhou 510663 People's Republic of China
| | - Meitao Duan
- School of Traditional Chinese Medicine, Southern Medical University Guangzhou 510515 People's Republic of China
- Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics Guangzhou 510515 People's Republic of China
| | - Dhafer S Zinad
- Applied Science Department, University of Technology Baghdad 10001 Iraq
| | - Ranjan K Mohapatra
- Department of Chemistry, Government College of Engineering Keonjhar Odisha 758002 India
| | - Ahmad J Obaidullah
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh 11451 Saudi Arabia
- Drug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University Riyadh 11451 Saudi Arabia
| | - Xiaoyi Wei
- Key Laboratory of Plant Resources Conservation and Sustainable Utilization, Guangdong Provincial Key Laboratory of Applied Botany, Chinese Academy of Sciences South China Botanical Garden Guangzhou 510650 People's Republic of China
| | - Manoj K Pradhan
- Department of Chemistry, Government College of Engineering Keonjhar Odisha 758002 India
| | - Debadutta Das
- Department of Chemistry, Sukanti Degree College Subarnapur Odisha 767017 India
| | - Venkataramana Kandi
- Department of Microbiology, Prathima Institute of Medical Sciences Karimnagar Telangana India
| | - Hany S Zinad
- Biosciences Institute, Faculty of Medical Science, Newcastle University NE2 4HH Newcastle upon Tyne UK
- Iraq Natural History Museum and Research Centre (INHM), University of Baghdad Baghdad Iraq
| | - Quanhong Zhu
- School of Traditional Chinese Medicine, Southern Medical University Guangzhou 510515 People's Republic of China
- Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics Guangzhou 510515 People's Republic of China
| |
Collapse
|
8
|
Vostrikov NS, Zagitov VV, Ivanov SP, Lobov AN, Gabdrakhmanova SF, Miftakhov MS. Fluorine containing analogues of cloprostenol. J Fluor Chem 2020. [DOI: 10.1016/j.jfluchem.2020.109552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|